Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including I...
Guardado en:
Autores principales: | Julie A Murphy, Jacklyn A Harris, Andrew J Crannage |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e1a90c822834423a44782c190dfd876 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013) -
Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: Fabricio González-Andrade, et al.
Publicado: (2010) -
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Kimberley Allen-Philbey, et al.
Publicado: (2021) -
The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Aliza Bitton Ben-Zacharia, et al.
Publicado: (2021) -
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012)